Free Newsletter
New boilerplate pacts proposed for cancer projects
Academic researchers, hospitals and biotech companies are frequently forced to bring in expensive legal help to lay the framework for joint cancer research projects. But now the Justice Department has signed off on a plan to come up with boilerplate study contracts. And the National Cancer Institute is supporting the standard contracts.
J&J CEO and Chairman Bill Weldon told the Wall Street Journal that the contract negotiations over new development programs often create a "bottleneck" that slows the process down. So Weldon and other big developers are using the CEO Roundtable on Cancer to push the simplified legal approach. They came up with the standard contract after analyzing 75 existing contracts that bore remarkably similar language. This new approach could save up to a year of wasted efforts and delays.
- read the report from the Wall Street Journal
Related Articles:
NSF crunches the (eroding) numbers on academic R&D
Glaxo decides bigger is better for cancer research
Breakthrough points to new cancer drug class
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceBiotech Research email newsletter for FREE!
Be the first to comment